{"id":"docetaxel-cisplatin","safety":{"commonSideEffects":[{"rate":"70-90","effect":"Neutropenia"},{"rate":"50-70","effect":"Anemia"},{"rate":"30-50","effect":"Thrombocytopenia"},{"rate":"40-60","effect":"Nausea and vomiting"},{"rate":"30-50","effect":"Peripheral neuropathy"},{"rate":"20-40","effect":"Nephrotoxicity"},{"rate":"10-30","effect":"Ototoxicity"},{"rate":"50-80","effect":"Alopecia"},{"rate":"20-40","effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL197201","moleculeType":"Small molecule","molecularWeight":"520.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel is a taxane that binds to beta-tubulin and prevents microtubule depolymerization, disrupting the mitotic spindle and causing cell cycle arrest in G2/M phase. Cisplatin is a platinum-based alkylating agent that forms DNA adducts and cross-links, preventing DNA replication and transcription. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"Docetaxel and cisplatin work together as a chemotherapy combination: docetaxel stabilizes microtubules to prevent cell division, while cisplatin cross-links DNA to prevent replication, both inducing cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:54.431Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic non-small cell lung cancer"},{"name":"Gastric cancer"},{"name":"Head and neck cancer"},{"name":"Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT07496190","phase":"PHASE2","title":"Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-01","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":59},{"nctId":"NCT06223568","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-10","conditions":"Squamous Cell Carcinoma of the Head and Neck, Oropharynx, Human Papillomavirus Viruses","enrollment":70},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT03493425","phase":"PHASE2","title":"Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-03-12","conditions":"Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","enrollment":82},{"nctId":"NCT02997332","phase":"PHASE1","title":"Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-03-30","conditions":"Head and Neck Cancers","enrollment":14},{"nctId":"NCT05027633","phase":"PHASE2","title":"Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-11-02","conditions":"Squamous Cell Carcinoma, the Nasal Cavity, Paranasal Sinuses","enrollment":35},{"nctId":"NCT07477756","phase":"","title":"A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-09-04","conditions":"Prostate Cancer","enrollment":1247},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT05633667","phase":"PHASE2","title":"Study of Novel Treatment Combinations in Patients With Lung Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-03-16","conditions":"Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer","enrollment":270},{"nctId":"NCT01810913","phase":"PHASE2, PHASE3","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-22","conditions":"Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7","enrollment":613},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT06947668","phase":"","title":"Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel","status":"RECRUITING","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2025-05-01","conditions":"Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of the Hypopharynx, Larynx Squamous Cell Carcinoma","enrollment":250},{"nctId":"NCT07209189","phase":"PHASE2","title":"Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-04","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer","enrollment":75},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT04030455","phase":"PHASE2","title":"Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-07","conditions":"Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8","enrollment":28},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT00707473","phase":"PHASE2","title":"Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-06-16","conditions":"Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma","enrollment":31},{"nctId":"NCT06632327","phase":"PHASE3","title":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-12-11","conditions":"Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":1100},{"nctId":"NCT00588770","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08-08","conditions":"Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":403},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT07435311","phase":"PHASE1","title":"A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2020-06-15","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":118},{"nctId":"NCT07435324","phase":"PHASE3","title":"A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2024-08-08","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":161},{"nctId":"NCT05753306","phase":"PHASE2","title":"Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-04-20","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":40},{"nctId":"NCT07402538","phase":"PHASE3","title":"Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-24","conditions":"Oral Cancer, Oropharyngeal Cancer","enrollment":184},{"nctId":"NCT06592599","phase":"PHASE2","title":"Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-09-03","conditions":"Nasopharyngeal Carcinoma","enrollment":24},{"nctId":"NCT07392320","phase":"PHASE2","title":"A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-04","conditions":"Nasopharangeal Cancer","enrollment":142},{"nctId":"NCT02486718","phase":"PHASE3","title":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2015-10-31","conditions":"Non-Small Cell Lung Cancer","enrollment":1280},{"nctId":"NCT07381829","phase":"PHASE1","title":"A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer","status":"RECRUITING","sponsor":"HC Biopharma Inc.","startDate":"2025-10-27","conditions":"Advanced Solid Tumor Cancer","enrollment":328},{"nctId":"NCT06484491","phase":"NA","title":"IMPT Dose Escalation for NSCLC (HyDose)","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2025-09-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":87},{"nctId":"NCT06952621","phase":"PHASE3","title":"Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2026-02-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":390},{"nctId":"NCT07214987","phase":"PHASE2","title":"PDT For Induction Therapy For Head And Neck Cancer","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-09","conditions":"Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":26},{"nctId":"NCT05500092","phase":"PHASE2","title":"An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2023-01-25","conditions":"Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","enrollment":17},{"nctId":"NCT07371897","phase":"PHASE3","title":"Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-06-30","conditions":"Head and Neck Squamous Cell Carcinoma HNSCC","enrollment":154},{"nctId":"NCT07358689","phase":"PHASE2","title":"Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-30","conditions":"NSCLC","enrollment":120},{"nctId":"NCT07351565","phase":"PHASE1","title":"Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chang Chen","startDate":"2026-01-10","conditions":"Non-Small Cell Lung Cancer","enrollment":22},{"nctId":"NCT07328854","phase":"PHASE3","title":"40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-20","conditions":"Nasopharyngeal Carcinoma","enrollment":346},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT02998528","phase":"PHASE3","title":"A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-04","conditions":"Non Small Cell Lung Cancer","enrollment":505},{"nctId":"NCT06839378","phase":"NA","title":"Flura-seq for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei","status":"COMPLETED","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2025-02-17","conditions":"Pseudomyxoma Peritonei","enrollment":36},{"nctId":"NCT04367311","phase":"PHASE2","title":"Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nasser Hanna","startDate":"2020-05-22","conditions":"Lung Cancer, NSCLC","enrollment":100},{"nctId":"NCT05494190","phase":"NA","title":"The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2022-11-01","conditions":"Hypopharyngeal Carcinoma","enrollment":111},{"nctId":"NCT01154920","phase":"PHASE2","title":"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":128},{"nctId":"NCT06724042","phase":"PHASE1","title":"Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"InSilico Medicine Hong Kong Limited","startDate":"2026-06-30","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Advanced and/or Metastatic Solid Tumors","enrollment":159},{"nctId":"NCT06241456","phase":"PHASE1","title":"FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Fate Therapeutics","startDate":"2024-01-05","conditions":"Advanced Solid Tumor","enrollment":351},{"nctId":"NCT05664971","phase":"PHASE1, PHASE2","title":"JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-02-09","conditions":"Advanced Lung Cancer","enrollment":119},{"nctId":"NCT05516914","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2022-09-01","conditions":"Malignant Tumors","enrollment":490},{"nctId":"NCT01927744","phase":"PHASE2","title":"Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-12-16","conditions":"Head and Neck Cancer","enrollment":55},{"nctId":"NCT04854499","phase":"PHASE2","title":"Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-09-07","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":193},{"nctId":"NCT03582475","phase":"PHASE1","title":"Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-01-11","conditions":"Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma","enrollment":15},{"nctId":"NCT02495896","phase":"PHASE1","title":"Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2015-09-03","conditions":"Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma","enrollment":61},{"nctId":"NCT05541016","phase":"PHASE2","title":"De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-02-21","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":455},{"nctId":"NCT02572843","phase":"PHASE2","title":"Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2016-06-16","conditions":"NSCLC Non-small Cell Lung Cancer","enrollment":68},{"nctId":"NCT02817633","phase":"PHASE1","title":"A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tesaro, Inc.","startDate":"2016-07-08","conditions":"Neoplasms","enrollment":463},{"nctId":"NCT06623656","phase":"PHASE2","title":"Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2025-02-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":112},{"nctId":"NCT04025879","phase":"PHASE3","title":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-11-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":461},{"nctId":"NCT06699212","phase":"PHASE3","title":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases","status":"RECRUITING","sponsor":"Rakuten Medical, Inc.","startDate":"2024-12-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":412},{"nctId":"NCT05020457","phase":"PHASE2","title":"SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2021-12-07","conditions":"Non Small Cell Lung Cancer","enrollment":69},{"nctId":"NCT06463665","phase":"PHASE2","title":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2024-09-26","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":142},{"nctId":"NCT04722523","phase":"PHASE1","title":"A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-01-20","conditions":"Head and Neck Cancer, Head Cancer, Head Cancer Neck","enrollment":40},{"nctId":"NCT06531434","phase":"PHASE1, PHASE2","title":"Establishing Best Treatment Strategy for T4 Esophageal Cancer","status":"RECRUITING","sponsor":"National Cheng-Kung University Hospital","startDate":"2024-08-01","conditions":"Esophageal Cancer TNM Staging Primary Tumor (T) T4","enrollment":22},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT07171528","phase":"PHASE2","title":"Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-09-10","conditions":"Ovarian Cancer","enrollment":80},{"nctId":"NCT00210171","phase":"PHASE2","title":"Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Institut Bergonié","startDate":"2004-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":""},{"nctId":"NCT06865339","phase":"PHASE2","title":"Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Nitin Ohri","startDate":"2025-08-07","conditions":"NSCLC, Locally Advanced","enrollment":76},{"nctId":"NCT03340896","phase":"PHASE3","title":"Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2015-06-25","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":256},{"nctId":"NCT06207981","phase":"PHASE3","title":"Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2024-02-26","conditions":"Anal Cancer","enrollment":310},{"nctId":"NCT04356170","phase":"PHASE2","title":"Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2021-02-04","conditions":"Cancer of Head and Neck","enrollment":105},{"nctId":"NCT00334815","phase":"PHASE2","title":"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-15","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma","enrollment":29},{"nctId":"NCT07139041","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Chang Chen","startDate":"2025-10","conditions":"NSCLC (Non-small-cell Lung Cancer)","enrollment":69},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT00665392","phase":"PHASE2","title":"Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2008-02-01","conditions":"Head and Neck Cancer","enrollment":42},{"nctId":"NCT05156970","phase":"PHASE2","title":"Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC","status":"COMPLETED","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2021-06-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":81},{"nctId":"NCT07088484","phase":"","title":"Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-01","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT07063329","phase":"PHASE1, PHASE2","title":"Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive","status":"NOT_YET_RECRUITING","sponsor":"Avistone Pharmaceutical（Ningbo）Co., LTD.","startDate":"2025-08-08","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":108},{"nctId":"NCT07001618","phase":"PHASE2","title":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":162},{"nctId":"NCT06902272","phase":"PHASE2","title":"ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-06-11","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07055841","phase":"PHASE2","title":"Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Xiuping Ding","startDate":"2023-04-01","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":69},{"nctId":"NCT04062708","phase":"PHASE2","title":"CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2021-03-10","conditions":"Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer","enrollment":38},{"nctId":"NCT07050043","phase":"PHASE3","title":"Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC","status":"RECRUITING","sponsor":"Dr Arvindran A/L Alaga","startDate":"2025-05-19","conditions":"NSCLC (Non-small Cell Lung Carcinoma), First Line Therapy, Locally Advanced/Metastatic NSCLC","enrollment":123},{"nctId":"NCT03519295","phase":"PHASE2","title":"A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2018-07-03","conditions":"Anal Cancer","enrollment":97},{"nctId":"NCT07041788","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2025-07-10","conditions":"Cancer","enrollment":25},{"nctId":"NCT00076310","phase":"PHASE2","title":"OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-01-28","conditions":"Head and Neck Cancer","enrollment":50},{"nctId":"NCT06940180","phase":"PHASE2","title":"Toripalimab With Chemotherapy for Sinus Cancer","status":"RECRUITING","sponsor":"Glenn J. Hanna","startDate":"2025-06-17","conditions":"Sinonasal Cancer, Paranasal Sinus Neoplasms, Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT05726370","phase":"PHASE2","title":"Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-05-20","conditions":"Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma","enrollment":28},{"nctId":"NCT06311981","phase":"PHASE2","title":"Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-08-08","conditions":"Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy","enrollment":29},{"nctId":"NCT06311968","phase":"PHASE2","title":"The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-05-06","conditions":"Thymus Epithelial Tumor, Proton Radiotherapy, Radiation Toxicity","enrollment":55},{"nctId":"NCT06186726","phase":"PHASE2","title":"Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-01-26","conditions":"Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy","enrollment":48},{"nctId":"NCT06311955","phase":"PHASE2","title":"Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2025-07-01","conditions":"Thymic Epithelial Tumor, Radiotherapy Side Effect, Carbon Ion Radiotheray","enrollment":48},{"nctId":"NCT04634877","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-01-10","conditions":"Endometrial Neoplasms","enrollment":990},{"nctId":"NCT06943820","phase":"PHASE1, PHASE2","title":"AK129 Combination Therapy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-05-21","conditions":"Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma","enrollment":230},{"nctId":"NCT03914443","phase":"PHASE1","title":"A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma","status":"COMPLETED","sponsor":"National Cancer Center, Japan","startDate":"2019-05-07","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma","enrollment":37},{"nctId":"NCT06277791","phase":"PHASE2","title":"The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Hospital of Stomatology, Wuhan University","startDate":"2023-08-19","conditions":"Clinical IVb Stage Oral Squamous Cell Carcinomas Patients","enrollment":35},{"nctId":"NCT03201861","phase":"PHASE3","title":"Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2017-07-27","conditions":"Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Duct Carcinoma of Breast","enrollment":762},{"nctId":"NCT04909164","phase":"","title":"The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2021-06-15","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":1500},{"nctId":"NCT00405405","phase":"PHASE1","title":"Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2006-12","conditions":"Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer","enrollment":13},{"nctId":"NCT06861712","phase":"PHASE2","title":"Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-06","conditions":"Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Stereotactic Body Radiation Therapy (SBRT)","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1083,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Taxotere","Platinol"],"phase":"phase_3","status":"active","brandName":"Docetaxel, Cisplatin","genericName":"Docetaxel, Cisplatin","companyName":"Samsung Medical Center","companyId":"samsung-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel and cisplatin work together as a chemotherapy combination: docetaxel stabilizes microtubules to prevent cell division, while cisplatin cross-links DNA to prevent replication, both inducing cancer cell death. Used for Advanced or metastatic non-small cell lung cancer, Gastric cancer, Head and neck cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}